trial
as of 2026-07-01A Bioequivalence Study of 15 mg ER OROS Paliperidone
NCTId NCT00892489
at a glance
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Completed
Enrollment
80 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
None
Start
2004-07
Primary completion
—
Eligibility
MALE · 18 Years · 55 Years
Interventions & indications
Drugs
Indications
Sponsors
Johnson & JohnsonLead Sponsor
Sites
0 total
Facts & assertions
3 sourced
Enrollment
80
Phase
PHASE1
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication